Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESELECT-I: Personalized Timing of IDS in Ovarian Cancer
NCT07023484Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of carboplatin, paclitaxel in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by The University of Hong Kong. Started May 2025; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT07023484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023484.